27.85
0.16 (0.58%)
| Previous Close | 27.69 |
| Open | 27.83 |
| Volume | 116,932 |
| Avg. Volume (3M) | 275,373 |
| Market Cap | 860,910,144 |
| Price / Sales | 2.54 |
| Price / Book | 0.720 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2025 |
| Profit Margin | -13.94% |
| Operating Margin (TTM) | -26.95% |
| Diluted EPS (TTM) | -1.33 |
| Quarterly Revenue Growth (YOY) | 13.90% |
| Total Debt/Equity (MRQ) | 0.74% |
| Current Ratio (MRQ) | 6.32 |
| Operating Cash Flow (TTM) | 9.36 M |
| Levered Free Cash Flow (TTM) | -42.21 M |
| Return on Assets (TTM) | -3.69% |
| Return on Equity (TTM) | -3.72% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | Fulgent Genetics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -1.30 |
|
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 33.42% |
| % Held by Institutions | 54.65% |
| 52 Weeks Range | ||
| Median | 30.00 (7.72%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 11 Nov 2025 | 30.00 (7.72%) | Hold | 28.38 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GAO HANLIN | - | 27.53 | -1,331 | -36,642 |
| KIM PAUL | - | 27.53 | -3,004 | -82,700 |
| XIE JIAN | - | 27.53 | -4,711 | -129,694 |
| Aggregate Net Quantity | -9,046 | |||
| Aggregate Net Value ($) | -249,036 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 27.53 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KIM PAUL | Officer | 26 Jan 2026 | Disposed (-) | 3,004 | 27.53 | 82,700 |
| XIE JIAN | Officer | 26 Jan 2026 | Disposed (-) | 4,711 | 27.53 | 129,694 |
| GAO HANLIN | Officer | 26 Jan 2026 | Disposed (-) | 1,331 | 27.53 | 36,642 |
| Date | Type | Details |
|---|---|---|
| 22 Dec 2025 | Announcement | Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |